Michael R. Bishop
迈克尔·毕肖普
MD
Professor of Medicine; Director, Hematopoietic Cellular Therapy Program医学教授；造血细胞治疗项目主任
👥Biography 个人简介
Michael R. Bishop, MD is a leading expert in cellular immunotherapy for aggressive B cell lymphomas at the University of Chicago. He was a principal investigator of the landmark ZUMA-7 trial demonstrating superiority of axicabtagene ciloleucel over standard-of-care salvage chemotherapy in second-line DLBCL, reshaping treatment paradigms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CAR-T Cell Therapy in DLBCL
Led pivotal ZUMA-7 phase III trial showing axi-cel achieves superior event-free survival over platinum-based salvage and autologous transplant in second-line relapsed/refractory large B cell lymphoma.
Cellular Therapy Program Development
Built a comprehensive hematopoietic cellular therapy program integrating CAR-T, allogeneic transplant, and novel immunotherapy approaches for lymphoid malignancies.
Representative Works 代表性著作
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)
New England Journal of Medicine (2022)
Phase III trial establishing axi-cel superiority over standard salvage + ASCT as second-line treatment for relapsed/refractory DLBCL.
Long-term outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Blood (2023)
Five-year follow-up of ZUMA-1 demonstrating durable remissions in heavily pre-treated DLBCL with manageable long-term safety profile.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 迈克尔·毕肖普 的研究动态
Follow Michael R. Bishop's research updates
留下邮箱，当我们发布与 Michael R. Bishop（University of Chicago Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment